| | |
| Clinical data | |
|---|---|
| Other names | 3,4-Norbornyl-2,5-DMPEA; 3,4-Norbornyl-2,5-dimethoxyphenethylamine; 2,5-Dimethoxy-3,4-norbornylphenethylamine; 3,6-Dimethoxy-4-(2-aminoethyl)benzonorbornane |
| Routes of administration | Oral [1] |
| Drug class | Serotonergic psychedelic; Hallucinogen |
| ATC code |
|
| Pharmacokinetic data | |
| Onset of action | 1–2 hours [1] [2] |
| Duration of action | 32–48 hours [1] [2] |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C15H21NO2 |
| Molar mass | 247.338 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
2C-G-5, also known as 3,4-norbornyl-2,5-dimethoxyphenethylamine, is a psychedelic drug of the phenethylamine and 2C families. [1] [3] [4] [5] [2] It is one of several homologues of 2C-G (3,4-dimethyl-2,5-dimethoxyphenethylamine). [1] [3] [4] [5] The drug is taken orally. [1] [3] [4] 2C-G-5 was encountered online as a novel designer drug in 2025. [2]
In his book PiHKAL (Phenethylamines I Have Known and Loved) and other publications, Alexander Shulgin lists 2C-G-5's dose as 10 to 16 mg orally and its duration as 32 to 48 hours. [1] [3] [4] [2] The drug's onset is 1 to 2 hours and its time to peak is 2.5 to 3 hours. [1] [2] 2C-G-5 is reported to produce psychedelic effects including visuals, clear and cosmic thinking, and 2C-B-like enhanced eroticism, among others. [1] [2] It is among the most potent of the 2C psychedelics. [1] [3] [4] However, its duration is described as too long, interfering with sleep and resulting in subsequent-day consequences like tiredness and sleepiness. [1] [2] 2C-G-5 was also the longest-lasting drug included in PiHKAL based on its specified duration. [1]
The chemical synthesis of 2C-G-5 has been described. [1]
Analogues of 2C-G-5 include other compounds of the 2C-G and Ganesha series, among others. [1]
2C-G-5 was first described in the literature by Alexander Shulgin in his 1991 book PiHKAL (Phenethylamines I Have Known and Loved). [1] [3] [4] [5] [2] It was encountered online as a novel designer drug in 2025. [2]